Product Description
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCI-2011-00282 | P2 |
Completed |
Melanoma |
2018-11-01 |
|
NCT00849875 | P2 |
Terminated |
Melanoma |
2014-11-17 |
|
NCT00896480 | P2 |
Completed |
Melanoma |
2014-11-03 |
|
PREDICT | P2 |
Completed |
Melanoma |
2012-06-27 |